Lumanity has officially joined the Digital Therapeutics Alliance (DTA).
The Digital Therapeutics Alliance is a global non-profit trade association with the mission of broadening the understanding, adoption, and integration of clinically-validated digital therapeutics into healthcare through education, advocacy, and research. The DTA envisions enabling broad access to high quality, evidence-based digital therapeutics for patients, healthcare providers, and payers in order to improve clinical and health economic outcomes. Digital therapeutics (DTx) are changing the healthcare delivery system with evidence-based technologies that improve patient outcomes.
The DTA brings together leading organizations to advance the adoption and integration of digital therapeutic products into traditional medicine. Member companies are aligned in the organization’s collective mission to improve clinical and health economic outcomes through the use of high quality, evidence-based digital therapeutics for patients, clinicians, and payors.
Lumanity has been supporting launches across the full spectrum of digital health solutions since 2016 and recently conducted a survey of ~65 payer decision makers on what it takes to secure coverage for these treatment advances.
For more information about the DTA, visit the DTA Alliance website.
